Hirotsugu Kenmotsu

List of Publications by Year
in descending order

51	1,636	331538 21	302012 39
papers	citations	h-index	g-index

52	52	52	2438
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1242-1246.	0.5	177
2	Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 512-519.	0.5	166
3	Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. PLoS ONE, 2013, 8, e67466.	1.1	151
4	Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Science, 2015, 106, 497-504.	1.7	123
5	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 2187-2196.	0.8	78
6	Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, singleâ€institute study. Cancer, 2014, 120, 1471-1481.	2.0	65
7	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemotherapy and Pharmacology, 2015, 75, 521-526.	1.1	62
8	A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. Journal of Thoracic Oncology, 2020, 15, 1935-1942.	0.5	50
9	Phase II study of nabâ€paclitaxelÂ+Âcarboplatin for patients with nonâ€smallâ€cell lung cancer and interstitial lung disease. Cancer Science, 2019, 110, 3738-3745.	1.7	49
10	Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. Investigational New Drugs, 2017, 35, 105-107.	1.2	45
11	Treatment Rationale and Design for J-SONIC: AÂRandomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Nonâ€“Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer, 2018, 19, e5-e9.	1.1	44
12	Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e247-e252.	1.1	41
13	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	0.9	36
14	Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncology, 2019, 15, 1911-1920.	1.1	36
15	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Cancer Science, 2018, 109, 2539-2548.	1.7	35
16	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. European Respiratory Journal, 2022, 60, 2200380.	3.1	34
17	A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small) Tj ETQq1 1 0.784314 rgBT /Overlock		
18	Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study. Anticancer Research, 2015, 35, 4259-63.	0.5	30

#	Article	IF	Citations
19	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer, 2014, 14, 18.	1.1	27
20	Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206. Journal of Clinical Oncology, 2020, 38, 4292-4301.	0.8	26
21	A Phase III Trial Comparing Irinotecan and Cisplatin with Etoposide and Cisplatin in Adjuvant Chemotherapy for Completely Resected Pulmonary High-grade Neuroendocrine Carcinoma (JCOG1205/1206). Japanese Journal of Clinical Oncology, 2014, 44, 379-382.	0.6	23
22	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. JTO Clinical and Research Reports, 2020, 1, 100020.	0.6	23
23	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e405-e414.	1.1	21
24	Modified <scp>GAP</scp> index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in nonâ€small cell lung cancer. Respirology, 2017, 22, 1379-1385.	1.3	20
25	Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 247-256.	1.3	20
26	Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study. PLoS ONE, 2019, 14, e0210074.	1.1	19
27	Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Nonâ€“Small-Cell Lung Cancer: The JIPANG Study Protocol. Clinical Lung Cancer, 2018, 19, e1-e3.	1.1	16
28	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANGâ€TR). Cancer Science, 2021, 112, 388-396.	1.7	16
29	Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study. Cancer Medicine, 2021, 10, 895-904.	1.3	16
30	ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. Lung Cancer, 2018, 121, 48-53.	0.9	15
31	The effects of advanced age and serum Î±₁â€acid glycoprotein on docetaxel unbound exposure and doseâ€limiting toxicity in cancer patients. British Journal of Clinical Pharmacology, 2017, 83, 2416-2425.	1.1	14
32	Treatment and relapse of interstitial lung disease in nivolumabâ€treated patients with nonâ€“small cell lung cancer. Cancer Science, 2021, 112, 1506-1513.	1.7	14
33	The incidence and risk factors of febrile neutropenia in chemotherapy-naÃ¯ve lung cancer patients receiving etoposide plus platinum. Cancer Chemotherapy and Pharmacology, 2017, 79, 1229-1237.	1.1	13
34	Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. Lung Cancer, 2019, 128, 152-157.	0.9	12
35	Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab. Investigational New Drugs, 2017, 35, 839-841.	1.2	10
36	Proposing synchronous oligometastatic nonâ€“smallâ€cell lung cancer based on progression after firstâ€line systemic therapy. Cancer Science, 2021, 112, 359-368.	1.7	10

#	Article	IF	Citations
37	Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.. Journal of Clinical Oncology, 2017, 35, 9078-9078.	0.8	10
38	Predictive value of EGFR mutation in nonâ€“smallâ€cell lung cancer patients treated with platinum doublet postoperative chemotherapy. Cancer Science, 2022, 113, 287-296.	1.7	10
39	Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for nonâ€“small cell lung cancer. Cancer Science, 2021, 112, 1495-1505.	1.7	8
40	Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia. Cancers, 2021, 13, 3979.	1.7	7
41	Predicting the efficacy of <scp>firstâ€line</scp> immunotherapy by combining cancer cachexia and tumor burden in advanced <scp>nonâ€small cell</scp> lung cancer. Thoracic Cancer, 2022, 13, 2064-2074.	0.8	7
42	Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer Medicine, 2021, 10, 2350-2358.	1.3	5
43	Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis. Investigational New Drugs, 2022, 40, 411-419.	1.2	5
44	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with nonâ€small cell lung cancer harboring EGFR mutation. Cancer Medicine, 2021, 10, 7503-7513.	1.3	4
45	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. Cancer Chemotherapy and Pharmacology, 2020, 85, 605-614.	1.1	3
46	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer, 2021, 21, 1121.	1.1	3
47	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer, 2021, 21, 1247.	1.1	3
48	Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Investigational New Drugs, 2021, 39, 1732-1741.	1.2	2
49	Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European Journal of Cancer, 2021, 151, 249-251.	1.3	1
50	Clinical impact of tumour burden on the efficacy of <scp>PD</scp> â€‘/ <scp>PDâ€‘L1</scp> inhibitors plus chemotherapy in nonâ€smallâ€cell lung cancer. Cancer Medicine, 0, , .	1.3	1
51	Reply to J. L. Derks et al. Journal of Clinical Oncology, 2021, 39, 1509-1510.	0.8	0